Haboro et al. J Infect Dis Epidemiol 2019, 5:077 Volume 5 | Issue 2 DOI: 10.23937/2474-3658/1510077 ISSN: 2474-3658 Journal of Infectious Diseases and Epidemiology Open Access Haboro et al. J Infect Dis Epidemiol 2019, 5:077 Citaton: Haboro GG, Handiso TB, Gebretsadik LA (2019) Health Care System Delay of Tuberculosis Treatment and Its Correlates among Pulmonary Tuberculosis Patents in Hadiya Zone Public Health Facilites, Southern Ethiopia. J Infect Dis Epidemiol 5:077. doi.org/10.23937/2474-3658/1510077 Received: March 7, 2019: Revised Received: March 29, 2019: Accepted: April 04, 2019: Published: April 06, 2019 Copyright: © 2019 Haboro GG, et al. This is an open-access artcle distributed under the terms of the Creatve Commons Atributon License, which permits unrestricted use, distributon, and reproducton in any medium, provided the original author and source are credited. • Page 1 of 6 • Health Care System Delay of Tuberculosis Treatment and Its Correlates among Pulmonary Tuberculosis Patents in Hadiya Zone Public Health Facilites, Southern Ethiopia Gedeyon Getahun Haboro 1 , Tilahun Beyene Handiso 2* and Lakew Abebe Gebretsadik 3 1 Hadiya Zone Health Department, Hossana, Ethiopia 2 Department of Epidemiology and Biostatstcs, Wolaita Sodo University, Ethiopia 3 Department of Health, Behavior and Society, Insttute of Health, Jimma University, Ethiopia *Corresponding authors: Tilahun Beyene Handiso, Department of Epidemiology and Biostatstcs, Wolaita Sodo University, Wolaita Sodo, Ethiopia, Tel: +251916356889 Abstract Background: Delay in TB treatment is signifcant to both disease prognoses at the individual level and within the community. Even though studies conducted in TB treatment delay there is result inconsistencies due to differences in culture, environment and infrastructure. Objective: The aim of the study was to assess health care system tuberculosis treatment Delay and associated factor among pulmonary tuberculosis patients. Method: Facility based cross sectional study triangulated by Qualitative data collection method. A total 340 PTB patients in Hadiya zone public health facilities included in the study. Health facilities were selected by Simple random sampling method from three woredas. DOTS user at the beginning of data collection was consecutively recruited in to the study until the intended sample size was fulflled. Multivariable binary Logistic regression was used. A P-value < 0.05 at 95% CI was considered statistical signifcance between dependent and predictor variables. Result: 340 PTB patients participated in this the study. 30% of the PTB patients faced health system delay. Visiting two or more health care providers (AOR: 3.40, 95% CI (1.910, 6.07), every trying other drug than TB drug (AOR: 4.0, 95% CI (2.144, 7.465) and prolonged referral (AOR: 3.004, 95% CI (1.59, 5.67) were independent predictors of delay. Conclusion: Prolonged referral, several visit of health care providers of two or more and ever used other drugs rather than Anti-TB drugs were found to have association with patient delay and health system delay. Keywords Health care system, Diagnosis and treatment delay, PTB Acronyms and Abbreviation CI: Confdence Interval; DOTS: Directly Observed Treat- ment Short-course; EPTB: Extra Pulmonary TB; HIV/AIDS: Human Immunodefciency Virus/Acquired Immunodefcien- cy Syndrome; HF: Health facility; NGOs: Non-Governmental Organizations; PTB: Pulmonary Tuberculosis; TB: Tubercu- losis, UN: United Nations; WHO: World Health Organization ReseARcH ARTicLe Check for updates Introducton Tuberculosis (TB) is an infectous bacterial disease caused by Mycobacterium TB which commonly afects the lungs but can afect other parts of the body. Though it afects peoples of all ages and sexes and poverty, mal- nutriton, overcrowding and human immunodefciency virus/acquired immunodefciency syndrome (HIV/AIDS) have been known for decades to make some groups more vulnerable to develop the disease [1,2]. Health system delay in our context was the tme ranging from patent’s frst contact to any modern health facility to date of initatons of Ant TB treatment. This comprises tme spent during referrals between facilites, diagnosis and tme between diagnosis and start of treatment and tme spent on treatment of patents with drugs other than that for TB [3].